Scarica l'app Stockscreener
78.11
3.86%
2.90
Dopo l'orario di chiusura:
78.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares in open market trade - Stock Titan
Cytokinetics, Inc. (CYTK) Stock Analysis: Tapping into a Potential 49% Upside in the Biotech Sector - DirectorsTalk Interviews
Cytokinetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $106.58, Implies 52% Upside - TradingView
Monashee Investment Management LLC Sells 25,000 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Acquired by GW&K Investment Management LLC - MarketBeat
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics EVP Malik sells $237,930 in shares By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $237,930 in shares - Investing.com India
Cytokinetics (CYTK) EVP exercises options and sells 3,500 shares - Stock Titan
Nonprofits can seek up to $20K from Cytokinetics for health equity - Stock Titan
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK) - Yahoo Finance
807,070 Shares in Cytokinetics, Incorporated $CYTK Acquired by Norges Bank - MarketBeat
Cytokinetics, Inc. (CYTK) Stock Analysis: A Promising Biotech Player with Potential 46.47% Upside - DirectorsTalk Interviews
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program - Yahoo Finance
Cytokinetics, Incorporated $CYTK Stake Trimmed by TD Asset Management Inc - MarketBeat
Total liabilities & shareholders' equities of Cytokinetics, Incorporated – XETR:KK3A - TradingView
CYTK Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesEarnings Power Value - newsline.com
Long term debt to total assets ratio of Cytokinetics, Incorporated – XETR:KK3A - TradingView
ETFs Investing in Cytokinetics, Incorporated Stocks - TradingView
Cytokinetics, Incorporated Trade Ideas — XETR:KK3A - TradingView
Cytokinetics prices $700 million stock offering at $71 per share - Investing.com
Truist raises Cytokinetics stock price target on positive trial data - Investing.com
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
Cytokinetics prices public offering of 9.8 mln shares at $71/share - marketscreener.com
Cytokinetics Inc (CYTK) News, Articles, Events & Latest Updates - Stocktwits
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report? - Yahoo Finance
BNP Paribas Financial Markets Purchases 332,397 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia
Cytokinetics director Parshall sells $370,400 of CYTK stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokineti - GuruFocus
Cytokinetics EVP Andrew Callos sells $1.11m in stock By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics director Edward Kaye sells $223,171 in shares By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.11m in stock - Investing.com
Cytokinetics director Edward Kaye sells $223,171 in shares - Investing.com
Cytokinetics director Parshall sells $370,400 of CYTK stock - Investing.com
Cytokinetics (CYTK) director Kaye sells 2,933 shares at $76.09 - Stock Titan
CYTOKINETICS (CYTK) CCO exercises options and sells 15,000 shares at $74.08 - Stock Titan
Director Parshall trims Cytokinetics (CYTK) stake with 5,000-share sale - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics (CYTK) Launches Myqorzo in Germany for Heart Condition Treatment - GuruFocus
Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy - marketscreener.com
Cytokinetics launches heart drug Myqorzo in Germany By Investing.com - Investing.com Australia
Cytokinetics launches heart drug Myqorzo in Germany - Investing.com
Cytokinetics Announces European Launch of MYQORZO® (aficamten) for Obstructive Hypertrophic Cardiomyopathy in Germany Following U.S. Approval - Quiver Quantitative
Cytokinetics launches Myqorzo® (aficamten) in European Union, with first commercial availability in Germany - marketscreener.com
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany - The Manila Times
New heart drug MYQORZO reaches German patients with obstructive HCM - Stock Titan
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):